Israel - Ibrani - Ministry of Health

csl behring ltd., israel - albutrepenonacog alfa - אבקה וממס להכנת תמיסה להזרקה - albutrepenonacog alfa 500 iu - coagulation factor ix

Israel - Ibrani - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 400 - 960 iu; coagulation factor vii (human) 200 - 500 iu; coagulation factor ix (human- rfixfc) 400 - 620 iu; coagulation factor x (human) 440 - 1200 iu; protein c 300 - 900 iu; protein s antigen 240 - 760 iu - coagulation factor ix, ii, vii and x in combination

Israel - Ibrani - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה וממס להכנת תמיסה להזרקה - c - 1 esterase inhibitor human 2000 iu/vial - c1- inhibitor,plasma derived

Israel - Ibrani - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה וממס להכנת תמיסה להזרקה - c - 1 esterase inhibitor human 3000 iu/vial - c1- inhibitor,plasma derived

Israel - Ibrani - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - linezolid - טבליה - linezolid 600 mg - linezolid

Israel - Ibrani - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

Israel - Ibrani - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

Israel - Ibrani - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - linezolid - טבליה - linezolid 600 mg - linezolid - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected. zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.

Israel - Ibrani - Ministry of Health

pfizer pharmaceuticals israel ltd - doxazosin as mesylate 1 mg - tablets - doxazosin - antihypertensive agent. benign prostatic hyperplasia.

Israel - Ibrani - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.